Emergent BioSolutions (EBS) Aandelenoverzicht
Emergent BioSolutions Inc., een biowetenschappelijk bedrijf, biedt oplossingen voor paraatheid en reactievermogen bij toevallige, opzettelijke en natuurlijk voorkomende bedreigingen van de volksgezondheid in de Verenigde Staten, Canada en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 5/6 |
| Toekomstige groei | 1/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 3/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
EBS Community Fair Values
Create NarrativeSee what 28 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Emergent BioSolutions Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$8.53 |
| 52 Week Hoogtepunt | US$14.06 |
| 52 Week Laag | US$5.62 |
| Bèta | 2.33 |
| 1 maand verandering | -6.47% |
| 3 maanden verandering | 2.77% |
| 1 Jaar Verandering | 33.70% |
| 3 jaar verandering | 12.68% |
| 5 jaar verandering | -86.62% |
| Verandering sinds IPO | -27.09% |
Recent nieuws en updates
Narratiefupdate • Jun 17
EBS: New Contracts And Funding Will Support Future Earnings Reset
Analysts have maintained their fair value estimate for Emergent BioSolutions at $12.00, making only minor adjustments to assumptions such as the discount rate, profit margin, and future P/E in the latest price target update. What’s in the News for Emergent BioSolutions Emergent BioSolutions secured a contract modification valued at approximately US$64.5 million from the U.S. Department of Health and Human Services’ ASPR division to supply BAT, its botulism antitoxin, under an existing 10 year agreement.Seeking Alpha • Jun 08
Emergent BioSolutions: Down 40%+ From Recent Highs And Likely More To Come
Summary Emergent BioSolutions remains under significant pressure, with persistent revenue, margin, and earnings declines across both Naloxone and Medical Counter-measures (MCM) segments. Competitive headwinds, reduced pricing power, and falling demand have driven Naloxone gross margins from 25% to 16% in Q1 2026, with unit sales and prices both declining. MCM revenues are lumpy, government-dependent, and in long-term decline, exposing EBS to unpredictable demand and minimal control over its core business drivers. I maintain a Sell rating, as cost-cutting and new manufacturing contracts are insufficient to offset deteriorating fundamentals and unclear long-term growth prospects. Read the full article on Seeking AlphaNarratiefupdate • Jun 02
EBS: Contract Wins And Funding Will Support Long Term Earnings Reset
Analysts now see Emergent BioSolutions as fairly valued at a reduced $12 price target, down from $15, indicating lower earnings expectations following the recent earnings miss. What's in the News Emergent received a contract modification worth about US$64.5 million from the U.S. Department of Health and Human Services for continued supply of its BAT botulism antitoxin to the Strategic National Stockpile.Recent updates
Narratiefupdate • Jun 17
EBS: New Contracts And Funding Will Support Future Earnings Reset
Analysts have maintained their fair value estimate for Emergent BioSolutions at $12.00, making only minor adjustments to assumptions such as the discount rate, profit margin, and future P/E in the latest price target update. What’s in the News for Emergent BioSolutions Emergent BioSolutions secured a contract modification valued at approximately US$64.5 million from the U.S. Department of Health and Human Services’ ASPR division to supply BAT, its botulism antitoxin, under an existing 10 year agreement.Seeking Alpha • Jun 08
Emergent BioSolutions: Down 40%+ From Recent Highs And Likely More To Come
Summary Emergent BioSolutions remains under significant pressure, with persistent revenue, margin, and earnings declines across both Naloxone and Medical Counter-measures (MCM) segments. Competitive headwinds, reduced pricing power, and falling demand have driven Naloxone gross margins from 25% to 16% in Q1 2026, with unit sales and prices both declining. MCM revenues are lumpy, government-dependent, and in long-term decline, exposing EBS to unpredictable demand and minimal control over its core business drivers. I maintain a Sell rating, as cost-cutting and new manufacturing contracts are insufficient to offset deteriorating fundamentals and unclear long-term growth prospects. Read the full article on Seeking AlphaNarratiefupdate • Jun 02
EBS: Contract Wins And Funding Will Support Long Term Earnings Reset
Analysts now see Emergent BioSolutions as fairly valued at a reduced $12 price target, down from $15, indicating lower earnings expectations following the recent earnings miss. What's in the News Emergent received a contract modification worth about US$64.5 million from the U.S. Department of Health and Human Services for continued supply of its BAT botulism antitoxin to the Strategic National Stockpile.Narratiefupdate • Apr 22
EBS: Earnings Reset And Buybacks Will Support Long Term Contract Upside
Narrative Update The consensus analyst price target for Emergent BioSolutions has been cut by $3 to $12. Analysts cite reduced earnings expectations after the recent earnings miss as the key driver of this change.Narratiefupdate • Apr 07
EBS: Earnings Reset And Buybacks Will Support Smallpox Contract Upside Potential
Analysts have trimmed their price target for Emergent BioSolutions to $12 from $15, citing reduced earnings expectations following the recent earnings miss. Analyst Commentary Bullish Takeaways Bullish analysts are keeping a positive stance on the shares even after the earnings miss, suggesting they still see room for upside from the current price level.Narratiefupdate • Mar 24
EBS: Earnings Reset And Buybacks Will Support Future Upside Potential
Analysts have trimmed their price target on Emergent BioSolutions to $12 from $15, citing lowered earnings expectations following the recent earnings miss. Analyst Commentary Analysts have reacted to the earnings miss by cutting their price target on Emergent BioSolutions to $12 from $15, reflecting reduced earnings expectations while still seeing room for potential upside at current levels.Narratiefupdate • Mar 09
EBS: Reset Earnings Bar And Buybacks Will Support Future Upside
Analysts have reduced their fair value estimate for Emergent BioSolutions to $12 from $13.50, citing lower earnings expectations after the recent miss, while also updating their assumptions for revenue growth, profit margins, and future P/E levels. Analyst Commentary Bullish Takeaways Bullish analysts are still comfortable assigning a fair value of $12, which suggests they see the earnings miss as an adjustment to expectations rather than a thesis-breaking event.Analyseartikel • Dec 23
Emergent BioSolutions Inc. (NYSE:EBS) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Despite an already strong run, Emergent BioSolutions Inc. ( NYSE:EBS ) shares have been powering on, with a gain of 28...Analyseartikel • Nov 27
Emergent BioSolutions (NYSE:EBS) Takes On Some Risk With Its Use Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyseartikel • Oct 08
Emergent BioSolutions Inc.'s (NYSE:EBS) Shares Bounce 31% But Its Business Still Trails The Industry
The Emergent BioSolutions Inc. ( NYSE:EBS ) share price has done very well over the last month, posting an excellent...Analyseartikel • Aug 24
Improved Revenues Required Before Emergent BioSolutions Inc. (NYSE:EBS) Stock's 29% Jump Looks Justified
Emergent BioSolutions Inc. ( NYSE:EBS ) shares have continued their recent momentum with a 29% gain in the last month...Analyseartikel • Aug 15
Emergent BioSolutions' (NYSE:EBS) Solid Earnings May Rest On Weak Foundations
NYSE:EBS 1 Year Share Price vs Fair Value Explore Emergent BioSolutions's Fair Values from the Community and select...Analyseartikel • Aug 10
Earnings Update: Here's Why Analysts Just Lifted Their Emergent BioSolutions Inc. (NYSE:EBS) Price Target To US$13.50
The investors in Emergent BioSolutions Inc. 's ( NYSE:EBS ) will be rubbing their hands together with glee today, after...Analyseartikel • Jul 05
Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • May 11
Emergent BioSolutions Inc.'s (NYSE:EBS) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Those holding Emergent BioSolutions Inc. ( NYSE:EBS ) shares would be relieved that the share price has rebounded 29...
Nieuw narratief • Apr 26
Transformational Initiatives Will Optimize Medical Countermeasures And Operations
Strategic refocus on medical countermeasures and NARCAN Nasal Spray aims to maintain market leadership and drive revenue growth.Seeking Alpha • Mar 26
Emergent BioSolutions: I See Further Downside Ahead In This Value Trap
Summary Emergent BioSolutions faces declining revenues, increasing competition, and limited growth potential, leading to a sell rating due to poor risk-reward profile. NARCAN, their main revenue generator, is experiencing pricing pressure and competition, with limited growth prospects outside North America. Management's plans for international expansion and future growth are vague and unlikely to succeed, further weakening the investment thesis. The company's financials show inconsistent revenue, declining profit margins, and reliance on asset sales, with no clear turnaround plan in sight. Read the full article on Seeking AlphaAnalyseartikel • Mar 21
Benign Growth For Emergent BioSolutions Inc. (NYSE:EBS) Underpins Stock's 31% Plummet
The Emergent BioSolutions Inc. ( NYSE:EBS ) share price has fared very poorly over the last month, falling by a...Seeking Alpha • Mar 20
Emergent BioSolutions: Attractive Biotech With Proven Business Clouded By Washington Funding Issues
Summary Emergent BioSolutions has faced significant challenges, with its stock price falling sharply since my previous article in July 2024. The company's updated mission focuses on combating health threats like smallpox, Ebola, anthrax, and opioid overdoses. I will evaluate Emergent's investment potential using Q4 2024 earnings reports, including its press release, conference call, 10-Q, and slides. This analysis aims to determine if Emergent's strategic goals align with its current financial performance and future prospects. Read the full article on Seeking AlphaAnalyseartikel • Mar 05
Is Emergent BioSolutions (NYSE:EBS) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Jan 22
There's No Escaping Emergent BioSolutions Inc.'s (NYSE:EBS) Muted Revenues Despite A 26% Share Price Rise
Emergent BioSolutions Inc. ( NYSE:EBS ) shareholders would be excited to see that the share price has had a great...Seeking Alpha • Jan 14
Emergent BioSolutions: Stock Is A Likely Winner In 2025
Summary Emergent BioSolutions has a sound turnaround strategy in place that is producing positive results. Emergent BioSolutions' cost-cutting efforts have the company on track for profitability in 2025. The undervaluation leaves plenty of room for the upside for the stock. Read the full article on Seeking AlphaAnalyseartikel • Nov 09
Emergent BioSolutions Inc. (NYSE:EBS) Shares Fly 32% But Investors Aren't Buying For Growth
Emergent BioSolutions Inc. ( NYSE:EBS ) shares have continued their recent momentum with a 32% gain in the last month...Seeking Alpha • Nov 08
Emergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa Magic
Summary Emergent BioSolutions' Q3 earnings report led to a 20% surge in its share price, now valued at ~$11 per share. The company's market cap is approximately $595 million, reflecting investor confidence post-earnings announcement. Emergent focuses on innovative preparedness and response solutions for various public health threats. The significant share price increase underscores market optimism about Emergent's strategic direction and financial performance. The presence of veteran Joe Papa as CEO is a reassuring one - his ability to complete business transformations is impressive. If the CEO stays, EBS stock price is likely to keep growing. Read the full article on Seeking AlphaAnalyseartikel • Oct 28
Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Seeking Alpha • Oct 04
Emergent BioSolutions: Strategic Shifts Present A Turnaround Scenario
Summary Emergent BioSolutions is showing signs of a potential turnaround with strategic restructuring, cost-cutting, and securing significant contracts in public health preparedness. Despite a challenging Q2, the company raised its full-year revenue forecast and is focusing on improving operational efficiency and reducing debt. Emergent's involvement in global health crises, like mpox, and securing FDA approvals and contracts, positions it as a key player in biodefense. Risks remain due to reliance on government contracts and ongoing restructuring, but recent positive developments support a cautiously optimistic outlook for long-term growth. Read the full article on Seeking AlphaAnalyseartikel • Sep 16
Little Excitement Around Emergent BioSolutions Inc.'s (NYSE:EBS) Revenues As Shares Take 27% Pounding
Emergent BioSolutions Inc. ( NYSE:EBS ) shares have retraced a considerable 27% in the last month, reversing a fair...Seeking Alpha • Aug 18
Emergent BioSolutions: Speculative Buy Amid Potential Monkeypox Vaccine Approval
Summary Emergent BioSolutions is a key player in public health. Its flagship product, NARCAN, is central to combating the opioid crisis. EBS’s stock rally is likely driven by its smallpox vaccine, ACAM2000, which has potential implications for monkeypox. Potential refinancing and strategic turnaround efforts mitigate the company's financial challenges, including significant debt and cash burn. EBS's MCM portfolio and new government contracts strengthen its position as a trusted biodefense partner. My speculative "buy" rating hinges on EBS’s ability to execute its turnaround, with added potential upside from its possible monkeypox vaccine approval. Read the full article on Seeking AlphaAnalyseartikel • Aug 02
Emergent BioSolutions Inc. (NYSE:EBS) Held Back By Insufficient Growth Even After Shares Climb 41%
Emergent BioSolutions Inc. ( NYSE:EBS ) shares have continued their recent momentum with a 41% gain in the last month...Rendement voor aandeelhouders
| EBS | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 8.7% | 7.5% | -2.5% |
| 1Y | 33.7% | 40.9% | 19.0% |
Rendement versus industrie: EBS presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 40.9 % opleverde.
Rendement versus markt: EBS overtrof de US markt, die het afgelopen jaar een rendement opleverde van 19 %.
Prijsvolatiliteit
| EBS volatility | |
|---|---|
| EBS Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: EBS heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van EBS is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1998 | 900 | Joe Papa | www.emergentbiosolutions.com |
Emergent BioSolutions Inc., een biowetenschappelijke onderneming, biedt oplossingen voor paraatheid en reactievermogen bij toevallige, opzettelijke en natuurlijk voorkomende bedreigingen van de volksgezondheid in de Verenigde Staten, Canada en internationaal. Het bedrijf is actief in de segmenten Commercial Products, MCM Products en All Other Revenues. Het bedrijf biedt ACAM2000, een pokken- en waterpokkenvaccin; Anthrax Immune Globulin Intravenous (ANTHRASIL), een polyklonaal antilichaamtherapeuticum voor de behandeling van inhalationele anthrax; Botulisme Antitoxine Heptavalent (BAT), een equine plasma antitoxine voor de behandeling van symptomatisch botulisme; BioThrax, een anthrax vaccin; CYFENDUS, een vaccin voor post-expositie profylaxe van ziekte na vermoedelijke of bevestigde blootstelling aan Bacillus anthracis; Ebanga, een monoklonaal antilichaam voor de behandeling van infectie veroorzaakt door Orthoebolavirus zairense; Raxibacumab injectie, een therapeutisch monoklonaal antilichaam voor de behandeling en profylaxe van inhalationele anthrax veroorzaakt door Bacillus anthracis; TEMBEXA, een oraal antiviraal middel voor de behandeling van pokkenziekte veroorzaakt door het variolavirus bij volwassen en pediatrische patiënten; en CNJ-016, een therapeutisch middel op basis van polyklonale antilichamen tegen complicaties van pokkenvaccinatie.
Emergent BioSolutions Inc. Samenvatting
| EBS fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$440.12m |
| Inkomsten(TTM) | -US$8.60m |
| Inkomsten(TTM) | US$676.80m |
0.7x
P/S-verhouding-51.2x
Koers/WinstverhoudingIs EBS overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| EBS resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$676.80m |
| Kosten van inkomsten | US$355.40m |
| Brutowinst | US$321.40m |
| Overige uitgaven | US$330.00m |
| Inkomsten | -US$8.60m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -0.17 |
| Brutomarge | 47.49% |
| Nettowinstmarge | -1.27% |
| Schuld/Eigen Vermogen Verhouding | 109.7% |
Hoe presteerde EBS op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/29 18:26 |
| Aandelenkoers aan het einde van de dag | 2026/06/26 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Emergent BioSolutions Inc. wordt gevolgd door 15 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Robert Wasserman | Benchmark Company |
| James Molloy | Brean Capital Historical (Janney Montgomery) |